DOCSLIB.ORG

2016 AAFP Guidelines for the Management of Feline Hyperthyroidism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2016 AAFP Guidelines for the Management of Feline Hyperthyroidism #&'$**)$"')*)""')*'*&)& >:?3 T+@T9::09?3 SPECIAL 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism Clinical context: Since 1979 and 1980 when the first reports of clinical feline hyperthyroidism (FHT) appeared in the literature, our understanding of the disease has evolved tremendously. Initially, FHT was a disease that only referral clinicians treated. Hazel C Carney Now it is a disease that primary clinicians routinely manage. Inclusion of the DVM MS DABVP (Canine/Feline) Co-Chair measurement of total thyroxine concentration in senior wellness panels, as well as in WestVet Emergency diagnostic work-ups for sick cats, now enables diagnosis of the condition long before the and Specialty Center, 5019 North Sawyer Avenue, cat becomes the classic scrawny, unkempt, agitated patient with a bulge in its neck. However, Garden City, ID 83617, USA earlier recognition of the problem has given rise to several related questions: how to recognize the health Email: [email protected] significance of the early presentations of the disease; how early to treat the disease; whether to treat FHT Cynthia R Ward when comorbid conditions are present; and how to manage comorbid conditions such as chronic kidney VMD PhD DACVIM disease and cardiac disease with treatment of FHT. The 2016 AAFP Guidelines for the Management of Feline Co-Chair University of Georgia, Hyperthyroidism (hereafter referred to as the Guidelines) will shed light on these questions for the general College of Veterinary Medicine, practitioner and suggest when referral may benefit the cat. 2200 College Station Road, Athens, GA 30605, USA Scope: The Guidelines explain FHT as a primary disease process with compounding factors, and provide Email: [email protected] a concise explanation of what we know to be true about the etiology and pathogenesis of the disease. Steven J Bailey The Guidelines also: DVM DABVP (Feline) < Distill the current research literature into simple recommendations for testing sequences that will avoid Exclusively Cats Veterinary misdiagnosis and separate an FHT diagnosis into six clinical categories with associated management strategies. Hospital, 6650 Highland Road, Ste 116, Waterford, < Emphasize the importance of treating all hyperthyroid cats, regardless of comorbidities, and outline the MI 48327, USA currently available treatments for the disease. David Bruyette < Explain how to monitor the treated cat to help avoid exacerbating comorbid diseases. DVM DACVIM Dispel some of the myths surrounding certain aspects of FHT and replace them with an evidence-based VCA West Los Angeles < Animal Hospital, narrative that veterinarians and their practice teams can apply to feline patients and communicate to their 1900 South Sepulveda Blvd, owners. Los Angeles, CA 90025, USA Evidence base: To help ensure better case outcomes, the Guidelines reflect currently available, Sonnya Dennis evidenced-based knowledge. If research is lacking, or if a consensus does not exist, the expert panel DVM DABVP (Canine/Feline) Stratham-Newfields Veterinary of authors has made recommendations based on their extensive, cumulative clinical experience. Hospital, 8 Main Street, Newfields, NH 03856, USA Duncan Ferguson VMD PhD DACVIM DACVCP Feline hyperthyroidism: LRFJQSLT;QRIQNTRISTDMQOMTJSHPJSTLIO;SJTPT=SME College of Veterinary Medicine – an overview KO;TQNHQJSNHSTOCTRIEMOQJTPJSNOGPLTQNTHPRLA?@3@2 University of Illinois, Department of Comparative Biosciences, 7ISTDMS=PKSNHSTOCT(-7TIPLTLRSPJQKETQNHMSPLSJ 3840 Veterinary Medicine Basic (SKQNST IEDSMRIEMOQJQLGT (-7 T CQMLRT <SHPGS ;OMKJ;QJSTLQNHSTRIOLSTCQMLRTMSDOMRL@TPNJTRIS Sciences Bldg, 2001 South Lincoln Avenue, Urbana, S=QJSNRTP<OFRT68TESPMLTPBO@T;ISNTRISTQNQRQPK JQLSPLSTQLTNO;TJQPBNOLSJTQNT?A80??A9TOCTOKJSM ?@> 6@40?? IL 61802, USA MSDOMRLT PDDSPMSJT QNT RIST KQRSMPRFMSA *RT ;PL HPRLTPMOFNJTRIST;OMKJA (-7TQLTRISTGOLR Amy Hinc PDDPMSNRT RIPRT RIQLT ;PLT PT NS;@T NORT FLRT PN HOGGONTSNJOHMQNSTJQLOMJSMTQNTGQJJKS1PBSJTOM VMD DABVP (Feline) FNJQPBNOLSJ@T JQLSPLST <SHPFLST DPRIOKOBQHPK OKJSMTHPRLTQNTRIST+@6@?> ;ISMSTQRLTDMS=PKSNHSTQL Cosmic Cat Veterinary Clinic, FDTROT?:TOCTHPRLTOKJSMTRIPNT?:TESPMLA6 220 East Main Street, Branford, CT 06405, USA 'KQNQHPKT MSDOMRLT CMOGT RIST SPMKET ?54:L There are several excellent recent reviews of A Renee Rucinsky JSLHMQ<SJT;IPRTQLTNO;T)NO;NTPLTRISTHKPLLQH@ the history, pathogenesis, epidemiology and DVM DABVP (Feline) Mid Atlantic Cat Hospital, incidence of FHT.3–5 This ‘overview’ section of 201 Grange Hall Road, the Guidelines highlights information from these Queenstown, MD 21658, USA prior publications and other sources deemed most relevant to a practitioner today. "*/ ?:A??22?:543?> ?3396>8> 400 JFMS CLINICAL PRACTICE T7IST&FRIOML T>:?3 S P E C I A L / 2016 AAFP feline hyperthyroidism guidelines LIO;LTRIPRTGOLRTIEDSMRIEMOQJTHPRLTLFCCSMTCMOG CONTENTS page PT COMGT OCT ROQHT NOJFKPMT BOQRSM@T LQGQKPMT RO < Feline hyperthyroidism: an overview 400 %KFGGSMLT JQLSPLST LSSNT QNT GPNAT 7IQLT QLT P < Diagnosis 402 <SNQBNTHONJQRQONTQNT;IQHITBMO;RITPNJTCFNH1 – Presenting signs, differential RQONTPMSTPFRONOGOFLA?2@?4 7OTJPRSTRISMSTPMSTNO diagnoses and diagnostic confirmation 402 )NO;NT MSDOMRLT OCT HPRLT SIQ<QRQNBT RIEMOQJ – Signalment, history and physical PFROPNRQ<OJQSL@TPLTPMSTDMSLSNRTQNTMP=SLTJQL1 examination 402 SPLSTQNTIFGPNLAT – A systematic and categorical 7IST GPOMQRET OCT IEDSMRIEMOQJT HPRLT IP=S approach to diagnosis 403 <QKPRSMPKTJQLSPLSAT$PMKETSDSMQSNHSTQNJQHPRSJ < Managing hyperthyroid cats with RIPRTMSGO=PKTOCTPTCFNHRQONPKTPJSNOGPTGQBIRT<S concurrent CKD 405 Hyperthyroidism COKKO;SJT <ET JS=SKODGSNRT OCT PT HONRMPKPRSMPK – Managing the cat that is non-azotemic ONSAT*CTP<KPRQ=STLFMBSMETOMTMPJQOQOJQNST;PLTNOR at initiation of treatment for affects HIOLSNT COMT GPNPBSGSNRT OCT RIST QNQRQPKT GPLL@ hyperthyroidism 405 up to 10% of LHQNRQBMPDIQHT S=QJSNHST LFBBSLRSJT RIPRT RIS – Managing the cat that is azotemic PJSNOGPT HOFKJT HONRQNFST ROT BMO;@T DOLLQ<KE at initiation of treatment for North American KSPJQNBT ROT GPKQBNPNHE@T PLT OHHFMLT QNT IFGPN hyperthyroidism 405 6@?50>> cats older DPRQSNRLA CTQGDOMRPNHSTROTRISTDMPHRQRQONSM@ < Managing hyperthyroid cats with ONKET>TOCTIEDSMRIEMOQJTHPRLTIP=STGPKQBNPNR concurrent heart disease 406 than 10 years. HPMHQNOGPLTPRTRISTRQGSTOCTQNQRQPKTJQPBNOLQLA>6@>9 < Treatment modalities 406 STJOTNORTESRTIP=STPTHKSPMTDQHRFMSTOCTRIS – Advantages and disadvantages of HPFLSLT OCT (-7T QNT QRLT HFMMSNRT DMSLSNRPRQONA feline hyperthyroidism treatments 407 .FKRQDKSTCPHROMLTDKPETPTMOKST<FRTRISTMSKPRQ=S < Radioactive iodine 407 QGDOMRPNHST OCT SPHIT QLT FN)NO;NA>:@>80>2 FM < Medical therapy 408 HFMMSNRTFNJSMLRPNJQNBTHPNT<STLFGGPMQ!SJTPL < Surgical thyroidectomy 409 COKKO;LATSNSRQHLTGPETQNCKFSNHSTLFLHSDRQ<QKQRE/ < Dietary therapy 410 QNTONSTLRFJE@T+QPGSLSTPNJTFMGSLST<MSSJLTIPJ < Monitoring hyperthyroid patients 410 PTJSHMSPLSJTMQL)TOCTJS=SKODQNBTRISTJQLSPLSA>3 < Prognosis 410 'IPNBSLTQNTHPRTIFL<PNJMETLQNHSTRIST?52:LTRO < Myths and realities of hyperthyroidism RISTDMSLSNRTJPE@TQNHKFJQNBTPTIQBISMTDSMHSNRPBS treatment 411 OCT QNJOOMT HPRL@T QNHMSPLSJT FRQKQ!PRQONT OC < Summary points 412 HOGGSMHQPKTHPRTCOOJLTPNJTKONBSMTKQCSTLDPNL@ < Appendix: Client brochure 415 GPETQNCKFSNHSTRISTDMS=PKSNHSA>80>2 &BSTIPLTKONB <SSNTFNJSMLROOJTROT<STPTMQL)TCPHROMTCOMTRIEMOQJ NOJFKST JS=SKODGSNRT QNT IFGPNLAT QKPRSMPK LS=SMSKETIEDSMGSRP<OKQHTHKQNQHPKTDMSLSNRPRQON JQLSPLSTLRMSNBRISNLTRISTIEDORISLSLTOCTJQSRPME (QBFMST? AT7ISTGOLRTQGDOMRPNRTHOGOM<QJQRQSL PNJT SN=QMONGSNRPKT SRQOKOBQSLT MPRISMT RIPN ;SMST HPMJQOMSLDQMPROMET JQLSPLSLA?6 *NT RIS GFRPRQONPKTHPFLSLTPKONSA?4 ?54:L@TRISTBMSPRSLRTPJ=PNHSLT;SMSTQNTKP<OMPRO1 $DQJSGQOKOBQHTLRFJQSLTIP=STDMOJFHSJTPTKQLRTOC ME@TMPJQOTBMPDIQHTPNJTSHIOHPMJQOBMPDIQHTS=PKF1 BFQKRT <ET PLLOHQPRQONT HOGDOFNJL@T GPNET OC PRQONTOCTRISTJQLSPLS@TPNJTRMSPRGSNRTCOHFLSJTON ;IQHIT PMST DISNOKLT OMT IPKOBSNPRSJT IEJMOHPM1 PNRQRIEMOQJT JMFBLT PNJT LFMBSMEAT*NT RIST ?55:L@ <ONLAT .OMST IEDSMRIEMOQJT HPRLT FLST JSOJOMQ!SJ MSDOMR LTOCTPDPRISRQH@TOHHFKRTSFRIEMOQNSGQH )QRRETKQRRSMTPNJOMTSPRTCOOJTCMOGTHPNLTRIPRTGPE 6@>4066T BOQRSM T PNJT LF<HKQNQHPKT IEDSMRIEMOQJQLG Figure 1 Severely HONRPQNT <QLDISNOKT &T PNJT DIRIPKPRSLA +OE SGSMBSJAT7ISTQNHKFLQONTOCTRORPKTLSMFGTRIEMO1 debilitated hyperthyroid cat: QLOCKP=ONSL@T PT HOGDONSNRT OCT GPNET HPRT COOJL@ this was a very common QNSTHONHSNRMPRQONTP<<MS=QPRSJTROT79TQNTRISLS clinical presentation in PNJT RIST HOGGONT SN=QMONGSNRPKT HONRPGQNPNR FQJSKQNSL TQNTCSKQNSTBSMQPRMQHTLHMSSNQNBTDPNSKL the 1980s and early 1990s. CQMS1MSRPMJPNRT%"$LTDOKE<MOGQNPRSJTJQDISNEK IPLTQNHMSPLSJTRISTMSHOBNQRQON Courtesy of Dr Hazel Carney SRISML T GPET PHRT PLT BOQRMOBSNL OCT RISLST ORISMT COMGLA =QPT RIEMOQJ1LRQGFKPRQNBT IOM1 SLSPMHIT HSNRSMLT <SBPNT MOF1 GONST7+- TLRQGFKPRQONTOMTPL RQNSKET OCCSMQNBT MPJQOPHRQ=S JQMSHRT GQROBSNLA6?069 PMQP<KS QOJQNST ?6?* T RISMPDET QNT RIS QOJQNSTHONRSNRTOCTHPRTCOOJLTPKLO SPMKET?55:L@T;QRITRISTCQMLRTLQB1 LSSGLTROTIP=STPNTQNCKFSNHSTON NQCQHPNRT MSDOMRT JSLHMQ<QNB RIST JS=SKODGSNRT OCT RIST JQL1 RIQLTRISMPDET<SQNBTDF<KQLISJ SPLSA68062 SHPFLST NOT LRFJQSL QNT ?558@?9 ;IQHIT HOQNHQJSJ IP=ST DMOLDSHRQ=SKET S=PKFPRSJ ;QRIT RIST SGSMBSNHST OCT DMQ1 KQCSKONBTSDOLFMSTROTPTLDSHQCQH =PRSTRMSPRGSNRTHSNRSMLA HOGDOFNJT QNT IEDSMRIEMOQJ +OGST HPRLT IP=ST PT HELRQH HPRL@TPJ=QLSTHPFRQOFLTHPRTO;N1 SNKPMBSGSNRT OCT RIST RIEMOQJ SMLT RIPRT PKKT PLLOHQPRQONLT PMS BKPNJT ;QRIOFRT IEDSMRIEMO1 HONSHRFMS@T PNJT NORT DMO=SN SGQPA?8@?3 -QLRODPRIOKOBE CPHRA JFMS CLINICAL PRACTICE 401 S P E C I A L / 2016 AAFP feline hyperthyroidism
Load more

Recommended publications
  • Evaluation of Thyroid to Background Ratios in Hyperthyroid Cats Ann Bettencourt
    Evaluation of Thyroid to Background Ratios in Hyperthyroid Cats Ann Bettencourt Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Biomedical and Veterinary Sciences Gregory Daniel David Panciera Marti Larson July 2, 2014 Blacksburg, VA Keywords: Pertechnetate, Radioiodine, Thyroid:Background Ratio, Scintigraphy, Feline, Thyroid Evaluation of Thyroid to Background Ratios in Hyperthyroid Cats Ann Bettencourt Abstract Hyperthyroidism is the most common feline endocrinopathy. 131I is the treatment of choice, and over 50,000 cats have been treated using an empirical fixed dose. Better treatment responses could be achieved by tailoring the dose based on the severity of disease. Scintigraphy is the best method to quantify the severity of the disease. Previously established scintigraphic quantitative methods, thyroid to salivary ratio (T:S ratio) and % dose uptake, are the most widely recognized measurements. Recently, the thyroid to background ratio (T:B ratio) has been proposed as an alternate method to assess function and predict 131I treatment response. The purpose of this study was to determine the best location of a background ROI, which should be reflective of blood pool activity. We also hypothesized that the T:B ratio using the determined background ROI would provide improved correlation to T4 when compared to T:S ratio and % dose uptake in hyperthyroid cats. Fifty-six hyperthyroid cats were enrolled. T4 was used as the standard measure of thyroid function and was obtained prior to thyroid scintigraphy and 131I therapy. Blood samples were collected at the time of scintigraphy and radioactivity within the sample was measured.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Fate of Sodium Pertechnetate-Technetium-99M
    JOURNAL OF NUCLEAR MEDICINE 8:50-59, 1967 Fate of Sodium Pertechnetate-Technetium-99m Dr. Muhammad Abdel Razzak, M.D.,1 Dr. Mahmoud Naguib, Ph.D.,2 and Dr. Mohamed El-Garhy, Ph.D.3 Cairo, Egypt Technetium-99m is a low-energy, short half-life iostope that has been recently introduced into clinical use. It is available as the daughter of °9Mowhich is re covered as a fission product or produced by neutron bombardement of molyb denum-98. The aim of the present work is to study the fate of sodium pertechnetate 9OmTc and to find out any difference in its distribution that might be caused by variation in the method of preparation of the parent nuclide, molybdenum-99. MATERIALS & METHODS The distribution of radioactive sodium pertechnetate milked from 99Mo that was obtained as a fission product (supplied by Isocommerz, D.D.R.) was studied in 36 white mice, weighing between 150 and 250 gm each. Normal isotonic saline was used for elution of the pertechnetate from the radionuclide generator. The experimental animals were divided into four equal groups depending on the route of administration of the radioactive material, whether intraperitoneal, in tramuscular, subcutaneous or oral. Every group was further subdivided into three equal subgroups, in order to study the effect of time on the distribution of the pertechnetate. Thus, the duration between administration of the radio-pharma ceutical and sacrificing the animals was fixed at 30, 60 and 120 minutes for the three subgroups respectively. Then the animals were dissected and the different organs taken out.Radioactivityin an accuratelyweighed specimen from each organ was estimated in a scintillation well detector equipped with one-inch sodium iodide thallium activated crystal.
    [Show full text]
  • Package Insert TECHNETIUM Tc99m GENERATOR for the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceuti
    NDA 17693/S-025 Page 3 Package Insert TECHNETIUM Tc99m GENERATOR For the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceutical For intravenous use only Rx ONLY DESCRIPTION The technetium Tc99m generator is prepared with fission-produced molybdenum Mo99 adsorbed on alumina in a lead-shielded column and provides a means for obtaining sterile pyrogen-free solutions of sodium pertechnetate Tc99m injection in sodium chloride. The eluate should be crystal clear. With a pH of 4.5-7.5, hydrochloric acid and/or sodium hydroxide may have been used for Mo99 solution pH adjustment. Over the life of the generator, each elution will provide a yield of > 80% of the theoretical amount of technetium Tc99m available from the molybdenum Mo99 on the generator column. Each eluate of the generator should not contain more than 0.0056 MBq (0.15 µCi) of molybdenum Mo99 per 37 MBq, (1 mCi) of technetium Tc99m per administered dose at the time of administration, and not more than 10 µg of aluminum per mL of the generator eluate, both of which must be determined by the user before administration. Since the eluate does not contain an antimicrobial agent, it should not be used after twelve hours from the time of generator elution. PHYSICAL CHARACTERISTICS Technetium Tc99m decays by an isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging studies is listed in Table 1. Table 1. Principal Radiation Emission Data1 Radiation Mean %/Disintegration Mean Energy (keV) Gamma-2 89.07 140.5 1Kocher, David C., “Radioactive Decay Data Tables,” DOE/TIC-11026, p.
    [Show full text]
  • EANM Practice Guideline/SNMMI Procedure Standard for RAIU and Thyroid Scintigraphy
    European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:2514–2525 https://doi.org/10.1007/s00259-019-04472-8 GUIDELINES EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy Luca Giovanella 1,2 & Anca M. Avram3 & Ioannis Iakovou4 & Jennifer Kwak5 & Susan A. Lawson3 & Elizabeth Lulaj6 & Markus Luster7 & Arnoldo Piccardo8 & Matthias Schmidt9 & Mark Tulchinsky10 & Frederick A. Verburg7 & Ely Wolin11 Received: 11 July 2019 /Accepted: 29 July 2019 / Published online: 7 August 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Introduction Scintigraphic evaluation of the thyroid gland enables determination of the iodine-123 iodide or the 99mTc-pertechnetate uptake and distribution and remains the most accurate method for the diagnosis and quantification of thyroid autonomy and the detection of ectopic thyroid tissue. In addition, thyroid scintigraphy and radioiodine uptake test are useful to discriminate hyperthyroidism from destructive thyrotoxicosis and iodine-induced hyperthyroidism, respectively. Methods Several radiopharmaceuticals are available to help in differentiating benign from malignant cytologically indeterminate thyroid nodules and for supporting clinical decision-making. This joint practice guideline/procedure standard from the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides recommendations based on the available evidence in the literature. Conclusion The purpose of this practice guideline/procedure standard is to assist imaging specialists and clinicians in recommending, performing, and interpreting the results of thyroid scintigraphy (including positron emission tomography) with various radiopharmaceuticals and radioiodine uptake test in patients with different thyroid diseases. Keywords Thyroid . Scintigraphy . Radioiodine uptake test . 99mTc-sestaMIBI, 18F-fluorodeoxyglucose Preamble approval of the Committee on Guidelines and Board of Directors of both organizations.
    [Show full text]
  • Hypothyroidism
    Hypothyroidism Alejandro Diaz, MD,*† Elizabeth G. Lipman Diaz, PhD, CPNP‡ *Miami Children’s Hospital, Miami, FL †The Herbert Wertheim College of Medicine, Florida International University, Miami, FL ‡University of Miami School of Nursing and Health Studies, Miami, FL Educational Gap Congenital hypothyroidism is one the most common causes of preventable intellectual disability. Awareness that not all cases are detected by the newborn screening is important, particularly because early diagnosis and treatment are essential in preserving cognitive abilities. Objectives After completing this article, readers should be able to: 1. Identify the causes of congenital and acquired hypothyroidism in infants and children. 2. Interpret an abnormal newborn screening result and understand indications for further evaluation and treatment. 3. Recognize clinical signs and symptoms of hypothyroidism. 4. Understand the importance of early diagnosis and treatment of congenital hypothyroidism. 5. Understand the presentation, diagnostic process, treatment, and prognosis of Hashimoto thyroiditis. 6. Differentiate thyroid-binding globulin deficiency from central hypothyroidism. AUTHOR DISCLOSURE Drs Diaz and Lipman Diaz have disclosed no financial relationships 7. Identify sick euthyroid syndrome and other causes of abnormal thyroid relevant to this article. This commentary does function test results. not contain a discussion of an unapproved/ investigative use of a commercial product/ device. ABBREVIATIONS CH congenital hypothyroidism BACKGROUND FT3 free triiodothyronine FT4 free thyroxine The thyroid gland produces hormones that have important functions related to energy HT Hashimoto thyroiditis metabolism, control of body temperature, growth, bone development, and maturation LT4 levothyroxine of the central nervous system, among other metabolic processes throughout the body. rT3 reverse triiodothyronine The thyroid gland develops from the endodermal pharynx.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ultra-TechneKow FM 2.15-43.00 GBq radionuclide generator 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium pertechnetate (99mTc) injection is produced by means of a (99Mo/99mTc) generator. Technetium (99mTc) decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.01 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. The radionuclide generator containing the parent isotope 99Mo, adsorbed on a chromatographic column delivers sodium pertechnetate (99mTc) injection in sterile solution. The 99Mo on the column is in equilibrium with the formed daughter isotope 99mTc. The generators are supplied with the following 99Mo activity amounts at activity reference time which deliver the following technetium (99mTc) amounts, assuming a 100% theoretical elution yield and 24 hours time from previous elution and taking into account that branching ratio of 99Mo is about 87%: 99mTc activity (maximum theoretical elutable 1.90 3.81 5.71 7.62 9.53 11.43 15.24 19.05 22.86 26.67 30.48 38.10 GBq activity at ART, 06.00 h CET) 99Mo activity (at ART, 06.00 h 2.15 4.30 6.45 8.60 10.75 12.90 17.20 21.50 25.80 30.10 34.40 43.00 GBq CET) The technetium (99mTc) amounts available by a single elution depend on the real yields of the kind of generator used itself declared by manufacturer and approved by National Competent Authority.
    [Show full text]
  • SODIUM PERTECHNETATE ( Tc) INJECTION (NON-FISSION
    Document QAS/08.283/FINAL-REV September 2009 RESTRICTED SODIUM PERTECHNETATE ( 99mTc) INJECTION (NON-FISSION): Revised Final text for addition to The International Pharmacopoeia (January September 2009) [Note from the Secretariat: This monograph was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 for addition to the 4 th Edition of the International Pharmacopoeia Further minor modifications have been applied to this text to be in line with the decisions taken when formatting the rest of the individual radiopharmaceuticals monographs] NATRII PERTECHNETATIS ( 99m Tc) SINE FISSIONE FORMATI INJECTIO SODIUM PERTECHNETATE ( 99mTc) INJECTION (NON-FISSION) This monograph applies to sodium pertechnetate ( 99m Tc) injection obtained from generators containing molybdenum-99 (99 Mo) produced by neutron irradiation of molybdenum and extracted from generator columns. Description. Sodium pertechnetate ( 99m Tc) injection (non-fission) is a clear, colourless solution. Technetium-99m has a half-life of 6.02 hours. Category. Diagnostic. Labelling. Label must state that the injection has been prepared from molybdenum-99 produced from non-fission. Level of molybdenum-99 per vial may be required. Additional information. Wherever V is used within the tests of this monograph, V is the maximum recommended dose , in millilitres . Requirements Complies with the monograph for “Parenteral Preparations” and with that for “Radiopharmaceuticals” . Document QAS/08.283/FINAL page 2 Definition. Sodium pertechnetate ( 99m Tc) injection (non-fission) is a sterile solution of technetium-99m in the form of pertechnetate ion, suitable for intravenous administration and that contains sufficient sodium chloride to make the solution isotonic with blood. The injection contains not less than 90% and not more than 110% of the content of technetium-99m stated on the label at the reference date and time stated on the label.
    [Show full text]
  • Mechanisms of Radiopharmaceutical Localization
    .::VOLUME 16, LESSON 4::. Mechanisms of Radiopharmaceutical Localization Continuing Education for Nuclear Pharmacists And Nuclear Medicine Professionals By James A. Ponto, MS, RPh, BCNP Chief Nuclear Pharmacists, University of Iowa Hospitals and Clinics and Professor (Clinical), University of Iowa Hospitals and Clinics The University of New Mexico Health Sciences Center, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program No. 0039-000-12-164- H04-P 2.5 Contact Hours or .25 CEUs. Initial release date: 7/19/2012 -- Intentionally left blank -- Mechanisms of Radiopharmaceutical Localization By James A. Ponto, MS, RPh, BCNP Editor, CENP Jeffrey Norenberg, MS, PharmD, BCNP, FASHP, FAPhA UNM College of Pharmacy Editorial Board Stephen Dragotakes, RPh, BCNP, FAPhA Michael Mosley, RPh, BCNP Neil Petry, RPh, MS, BCNP, FAPhA James Ponto, MS, RPh, BCNP, FAPhA Tim Quinton, PharmD, BCNP, FAPhA S. Duann Vanderslice, RPh, BCNP, FAPhA John Yuen, PharmD, BCNP Advisory Board Dave Engstrom, PharmD, BCNP Vivian Loveless, PharmD, BCNP, FAPhA Brigette Nelson, MS, PharmD, BCNP Brantley Strickland, BCNP Susan Lardner, BCNP Christine Brown, BCNP Director, CENP Administrator, CE & Web Publisher Kristina Wittstrom, MS, RPh, BCNP, FAPhA Christina Muñoz, M.A. UNM College of Pharmacy UNM College of Pharmacy While the advice and information in this publication are believed to be true and accurate at the time of press, the author(s), editors, or the publisher cannot accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, expressed or implied, with respect to the material contained herein.
    [Show full text]
  • Chloramphenicol Acetyltransferase Fusion Gene in Transgenic Mice
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 6176-6180, August 1990 Genetics Tissue-specific expression and methylation of a thyroglobulin- chloramphenicol acetyltransferase fusion gene in transgenic mice (chloramphenicol acetyltransferase assay/DNA methylation/thyroglobufin gene/transcription control cAMP) C. LEDENT*, M. PARMENTIER*, AND G. VASSART*t *Institut de Recherche Interdisciplinaire en Biologie Humaine et Nucleaire; and tService de Gdndtique Mddicale, Universitd Libre de Bruxelles, Campus Erasme, 808 Route de Lennik, 1070 Brussels, Belgium Communicated by M. Van Montagu, May 9, 1990 (received for review January 4, 1990) ABSTRACT Fusion genes containing 1600 or 2000 base of genes to correspond to the regions involved in the tissue pairs of the bovine thyroglobulin gene 5' flanking region and specificity of gene expression (14). the chloramphenicol acetyltransferase (CAT) coding sequence With the double aim ofcompleting the study on the Tg gene were constructed and used to generate transgenic mice. Alto- promoter and of designing a thyroid-specific vector, we gether, 24 independent transgenic lines were obtained, and the constructed Tg-chloramphenicol acetyltransferase (CAT) fu- expression ofthe transgene was assayed by measuring the CAT sion genes and tested their expression in transgenic mice. We activity in different tissues. Depending on the transgenic lines, demonstrate here that 1600 bp of the Tg gene promoter are the fusion gene was either silent in all tissues or specifically able to target the expression of a reporter gene to the thyroid expressed in the thyroid. The level of expression was found to gland and that the DH site is not necessary for this tissue- be highly variable from one line to another and to be regulated specific expression.
    [Show full text]
  • Snomed Ct Dicom Subset of January 2017 Release of Snomed Ct International Edition
    SNOMED CT DICOM SUBSET OF JANUARY 2017 RELEASE OF SNOMED CT INTERNATIONAL EDITION EXHIBIT A: SNOMED CT DICOM SUBSET VERSION 1.
    [Show full text]
  • 0Bcore Safety Profile
    Core Safety Profile Active substance: 99Mo/99mTc (Tc Generator) Pharmaceutical form(s)/strength: Radionuclide generator P-RMS: BE/H/PSUR/0013/002 Date of FAR: 30.09.2013 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients. Information on contraindications when using a kit for radiopharmaceutical preparation should be sought in the SmPC and PIL of the kit for radiopharmaceutical preparation. 4.4 Special warnings and precautions for use Potential for Hypersensitivity or anaphylactic reactions If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available. For each patient, exposure to ionising radiation must be justifiable on the basis of likely clinical benefit. The activity administered must be such that the resulting radiation is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result. Renal impairment, hepatic impairment Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible. Paediatric population For information on the use in paediatric population, see section 4.2. Careful consideration of the indication is required since the effective dose per MBq is higher than in adults (see section11). The use in children and adolescents has to be considered carefully, based upon clinical needs and assessing the risk/benefit ratio in this patient group. Thyroid blocking is of special importance when performing cerebral scintigraphy in the paediatric population.
    [Show full text]